NCT05810493

Brief Summary

The purpose of the study is to conduct a descriptive analysis of the population of patients with an interstitial lung disease received in the pulmonary department of University hospital of Nice (France). Analysis and documentation of clinical forms of the disease, therapeutics used and evolutions.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

March 29, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 12, 2023

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

May 10, 2023

Status Verified

March 1, 2023

Enrollment Period

4 years

First QC Date

March 29, 2023

Last Update Submit

May 9, 2023

Conditions

Interstitial Lung Disease

Outcome Measures

Primary Outcomes (1)

  • Build a retrospective cohort of patients with phenotyped interstitial Lung disease with longitudinal follow-up

    2 years

Secondary Outcomes (4)

  • Follow-up of progression criteria according to diagnosis

    2 years

  • Follow-up of progression criteria according to diagnosis

    2 years

  • Follow-up of progression criteria according to diagnosis

    2 years

  • Follow-up of progression criteria according to diagnosis

    2 years

Interventions

ObservationOTHER

Follow-up of disease, therapeutics and evolution

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

≥ 18 years old; Patients with a formal diagnosis or a provisional diagnosis of interstitial lung disease according to the mutlidisciplinary monthly meeting for interstitial lung disease occuring at University hospital of Nice, France

You may qualify if:

  • Age ≥ 18 years old
  • Diagnosis of interstitial lung disease according to the multidisciplinary monthly meeting for interstitial lung disease occuring at University hospital of Nice, France

You may not qualify if:

  • Patient-led opposition to data collection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital of Nice

Nice, 06200, France

RECRUITING

MeSH Terms

Conditions

Lung Diseases, Interstitial

Interventions

Observation

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Central Study Contacts

Sylvie LEROY, MD, PhD

CONTACT

+33 4 92 03 85 80leroy.s2@chu-nice.fr

ARC Pneumologie

CONTACT

+33 4 92 03 82 81ARCSpneumologie@chu-nice.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 29, 2023

First Posted

April 12, 2023

Study Start

January 1, 2022

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

May 10, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)